Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs

Journal of Medicinal Chemistry

Volumn 51, Issue 8, 2008, Pages 2412-2420

  Duan, Jian Xin ^a   Jiao, Hailong ^a   Kaizerman, Jacob ^a   Stanton, Timothy ^a   Evans, James W ^a   Lan, Leslie ^a   Lorente, Gustavo ^a   Banica, Monica ^a   Jung, Don ^a   Wang, Jinwei ^b   Ma, Huaiyu ^b   Li, Xiaoming ^b   Yang, Zhijian ^b   Hoffman, Robert M ^b   Ammons, W Steve ^a   Hart, Charles P ^a   Matteucci, Mark ^a  

^a Threshold Pharmaceuticals   (United States)

^b ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; PHOSPHORAMIDE MUSTARD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN METABOLISM; TUMOR XENOGRAFT;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICROSOMES, LIVER; PHOSPHORIC ACIDS; SOLUBILITY;

EID: 43049083694     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701028q     Document Type: Article

References (47)

1. Gillies, K. J.; Gatenby, R. A. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007, 26, 311-317.
2. Brown, J. M.; Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
3. Williams, K. J.; Cowen, R. L.; Brown, L. M.; Chinje, E. C.; Jaffar, M.; Stratford, I. J. Hypoxia in tumors: Molecular targets for anti-cancer therapeutics. Adv. Enzyme Regul. 2004, 44, 93-108.
4. Welsh, S. J.; Koh, M. Y.; Powis, G. The hypoxia inducible stress reponse as a target for cancer drug discovery. Semin. Oncol. 2006, 33, 486-497.
5. Boyle, R. G.; Travers, S. Hypoxia: Targeting the tumor. Anticancer Agents Med. Chem. 2006, 6, 281-286.
6. Ahn, G. O.; Brown, M. Targeting minors with hypoxia-activated cytotoxins. Front. Biosci. 2007, 12, 3483-3501.
7. McKeown, S. R.; Cowen, R. L.; Williams, K. J. Bioreductive drugs: From concept to clinic. Clin. Oncol. 2007, 19, 427-442.
8. Teicher, B. A.; Sartorelli, A. C. Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. J. Med. Chem. 1980, 23, 955-960.
9. Zeman, K. M.; Brown, J. M.; Lemmon, M. J.; Hirst, V. K.; Lee, W. W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol., Biol., Phys. 1986, 12, 1239-1242.
10. Denny, W. A.; Wilson, W. R. Tirapazamine: A bioreductive anticancer drug that exploits tumor hypoxia. Expert Opin. Invest. Drugs 2000, 9, 2889-2901.
11. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Intravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 641-649.
12. Kyle, A. H.; Minchimon, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213-220.
13. Hicks, K. O.; Pruijn, F. B.; Secomb, T. W.; Hay, M. P.; Hsu, R.; Brown, J. M.; Denny, W. A.; Dewhirst, M. W.; Wilson, W. R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 2006, 98, 1118-1128.
14. Gandara, D. R.; Lara, P. N., Jr.; Goldberg, Z.; Le, Q. T.; Mack, P. C.; Lau, D. H.; Gumerlock, P. H. Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin. Oncol. 2002, 29, 102-109.
15. Lalani, A. S.; Alters, S. E.; Wong, A.; Albertella, M. R.; Cleland, J. L.; Henner, W. D. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer. Clin. Cancer Res. 2007, 13, 2216-2225.
16. Patterson, A. V.; Ferry, D. M.; Edmunds, S. J.; Gu, Y.; Singleton, R. S.; Patel, K.; Pullen, S. M.; Hicks, K. O.; Syddall, S. P.; Atwell, G. J.; Yang, S.; Denny, W. A.; Wilson, W. R. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 2007, 13, 3922-3932.
17. Borch, R. F.; Liu, J.; Schmidt, J. P.; Marakovits, J. T.; Joswig, C.; Gipp, J. J.; Mulcahy, R. T. Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. J. Med. Chem. 2000, 43, 2258-2265.
18. Borch, R. F.; Liu, J.; Joswig, C.; Baggs, R. H.; Dexter, D. L.; Mangold, G. L. Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates. J. Med. Chem. 2001, 44, 74-77.
19. Colvin, O. M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 1999, 5, 555-560.
20. Zhang, J.; Tian, Q.; Yung Chan, S.; Chuen Li, S.; Zhou, S.; Duan, W.; Zhu, Y. Z. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 2005, 37, 611-703.
21. Bennewith, K. L.; Raleigh, J. A.; Durand, R. E. Orally administered Pimonidazole to label hypoxic tumor cells. Cancer Res. 2002, 62, 6827-6830.
22. Evans, S. M.; Judy, K. D.; Dunphy, I.; Jenkins, W. T.; Nelson, P. T.; Collins, R.; Wileyto, E. P.; Jenkins, K.; Hahn, S. M.; Stevens, C. W.; Judkins, A. R.; Phillips, P.; Geoerger, B.; Koch, C. J. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res. 2004, 64, 1886-1892.
23. Rajendran, J. G.; Mankoff, D. A. Beyond detection: Novel applications for PET imaging to guide cancer therapy. J. Nucl. Med. 2007, 48, 855-856.
24. Hay, M. P.; Sykes, B. M.; Denny, W. A.; Wilson, W. R. A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3H-benz|E|indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 1999, 9, 2237-2242.
25. Hay, M. P.; Wilson, W. R.; Denny, W. A. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg. Med. Chem. 2005, 13, 4043-4055.
26. Everett, S. A.; Naylor, M. A.; Patel, K. B.; Stratford, M. R.; Wardman, P. Bioreductively-activated prodrugs for targeting hypoxic tissues: Elimination of aspirin from 2-nitroimidazole derivatives. Bioorg. Med. Chem. Lett. 1999, 9, 1267-1272.
27. Fitzsimmons, S. A.; Workman, P.; Grever, M.; Paull, K.; Camalier, R.; Lewis, A. D. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9. J. Natl. Cancer Inst. 1996, 88, 259-269.
28. Schlager, J. J.; Powis, G. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol. Int. J. Cancer 1990, 45, 403-409.
29. Rosen, I., S.; Laxa, B.; Boulos, L.; Wiggins, L.; Keck, J. G.; Jameson, A. J.; Parra, R.; Patel, K.; Brown, G. L. Phase I study of TLK286 (Teleyta) administered weekly in advanced malignancies. Clin. Cancer Res. 2004, 10, 3689-3698.
30. Hay, M. P.; Anderson, R. F.; Ferry, D. M.; Wilson, W. R.; Denny, W. A. Synthesis und evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. J. Med. Chem. 2003, 46, 5533-5545.
31. Rooseboom, M.; Commandeur, J. N. M.; Vermeulen, N. P. E. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
32. Katz, M. H.; Takimoto, S.; Spivack, D.; Moossa, A. R.; Hoffman, R. M.; Bouvet, M. An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin. Exp. Metastasis 2004, 21, 7-12.
33. Bouvet, M.; Spernyak, J.; Katz, M. H.; Muzurchuk, R. V.; Takimoto, S.; Bernacki, R.; Rustum, Y. M.; Moossa, A. R.; Hoffman, R. M. High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65, 9829-9833.
34. Hoffman, R. H. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest. New Drugs 1999, 17, 343-359.
35. Fu, X.; Guadagni, F.; Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 5645-5649.
36. Wardman, P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 2001, 8, 739-761.
37. Wardman, P. The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Curr. Top. Radiat. Res. Q. 1977, 11, 347-398.
38. Paulson, O. B.; Melgaard, B.; Hansen, H. S.; Kamieniecka, Z.; Kohler, O.; Hansen, J. M.; Pedersen, A. G.; Tang, X.; Trojaborg, W. Misonidazole neuropathy. Acta Neurol. Scand. Suppl. 1984. 100, 133-136.
39. Naylor, M. A.; Threadgill, M. D.; Webb, P.; Stratford, I. J.; Stephens, M. A.; Fielden, E. M.; Adams, G. E. 2-Nitroimidazole dual-function bioreductive drugs: Studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives. J. Med. Chem. 1992, 35, 3573-3578.
40. Horwich, A.; Holliday, S. B.; Deacon, J. M.; Peckham, M. J. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitizer RSU-1069. Br. J. Radiol. 1986, 59, 1238-1240.
41. Suto, M. J.; Stier, M. A.; Werbel, L. M. Dual-function radiosensitizers. α-[|(2-Bromoethyl)amino|methyl|-2-nitro-1H-imidazole-1-ethanol and
42. related compounds: Preparation via an aziridine equivalent. J. Med. Chem. 1991, 34, 1207-1209.
43. Overgaard, J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 1994, 6, 509-518.
44. Papadopoulou, M. V.; Bloomer, W. D. NLCQ-1 (NSC 709257): Exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin. Cancer Res. 2003, 9, 5714-5720.
45. Bolton, J. L: McClelland, R. A. Kinetics and mechanism of the decomposition in aqueous solutions of 2-(hydroxyamino)imidazoles. J. Am. Chem. Soc. 1989, 111, 8172-8181.
46. Ludeman, S. M.; Boyd, V. L.; Regan, J. B.; Gallo, K. A.; Zon, G.; Ishii, K. Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of " phenylketophosphamide" and similar compounds related to the cyclophosphamide metabolite aklophosphamide. J. Med. Chem. 1986, 29, 716-727.
47. Struck, R. F.; Schmid, S. M.; Waud, W. R. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide. Cancer Chemother. Pharmacol. 1994, 34, 191-196.